Cielo study
A clinical trial to assess the effectiveness and safety of the drug satralizumab in patients with encephalitis, sponsored by Hoffmann-La Roche, one of the world’s largest biotech companies
Are you an encephalitis patient or a family member? Visit the CIELO Trial site for patients HERE
Are you a medical professional looking to refer a patient to the trial? Click the CIELO trial site for medical professionals HERE
Aim of the trial
The purpose of this study is to assess the effectiveness and safety of satralizumab in participants with anti-NMDAR encephalitis.
Trial locations
The trial currently has 67 medical centres that are actively recruiting, worldwide.
Click the link to find a medical centre near you!
Participant criteria
Be at least 12 years old and have been diagnosed with anti-NMDAR.
Symptoms started no longer than nine months ago.
Click the button below to read more about the CIELO trial.
What will taking part involve for the participants?
Everyone who joins this clinical trial will be put into one of two groups randomly and given either satralizumab or placebo via injection at weeks 0, 2 and 4, and then every four weeks until week 52.
Participants will have a 50% chance of being placed in either the satralizumab or placebo group.
Participants will be seen by the clinical trial doctor every four weeks to be given their clinical trial treatment and check to see how they are responding to the treatment.
How long will the trial last?
Depending on whether participants choose to take part in an optional extension period of the trial (which will last for at least two years), their total time in the clinical trial may last for up to five years (including follow-up appointments).
Participants are free to stop trial treatment and leave the clinical trial at any time.
How to take part or find out more?
Save the trial to share with your doctor, click the button below to share the study number with your healthcare team.